Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Patient received first two doses of Vivotif on consecutive days; Case reference number US-BN-2024-002269 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV24-1813) on 30-Jul-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication details were not provided. On 28-Jul-2024, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, orally for unknown indication. On 29-Jul-2024, one day after the first dose, the patient took the second dose of Vivotif (batch number: unknown), as reported, two doses out of four capsules, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240730-83305a to US-BAVARIAN NORDIC A/S-US-BN-2024-002269, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unknown age took the second dose of Vivotif for unknown indication, as reported one day after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age took the second dose of Vivotif for unknown indication, as reported one day after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.